Lupin Limited — Updates, 21-03-2025: Press Release

Nanomi B.V., a wholly-owned subsidiary of Lupin Limited, has received the CMO Award for Life Science Leadership in Drug Delivery during the recent DCAT week in New York. This prestigious award recognizes Nanomi's innovative approach to drug delivery, setting new industry benchmarks. Dr. Shahin Fesharaki, Global Chief Scientific Officer at Lupin, highlighted that this recognition reflects the company's commitment to advancing healthcare through innovation, particularly in delivering high-quality medicines that enhance patient outcomes. The CMO Leadership Awards are awarded based on feedback from sponsor companies who outsource manufacturing, making this acknowledgment particularly significant for Nanomi's reputation in the pharmaceutical landscape. This reinforces Lupin's strategic focus on innovation and its strong position in global markets, marking a positive development for future growth.